Mazdutide reduces percentage body weight by 12.42% in non-diabetic adults with obesity across five RCTs

BACKGROUND: Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity. METHODOLOGY: A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity. Meta-analysis was performed using RevMan 5.4 with random-effect models. RESULTS: Five RCTs were included. Mazdutide significantly reduced percentage body weight (MD = -12.42%, 95% CI: -16.15% to -8.68%), absolute body weight (MD = -9.76 kg, 95% CI: -13.15 to -6.37 kg) and waist circumference (MD = -7.98 cm, 95% CI: -10.24 to -5.72 cm). Systolic blood pressure (MD = -7.68 mmHg), total cholesterol (MD = -0.57 mmol/L) and LDL (MD = -0.37 mmol/L) also decreased. Adverse events were slightly increased (RR = 1.12). Dose-wise meta-regression showed significant effects (β = -0.99, 95% CI: -1.81 to -0.16; p = 0.0187). CONCLUSION: Mazdutide effectively reduces weight, waist circumference and blood pressure but may cause mild to moderate adverse events. Findings are limited by the small number of RCTs.